Actavis to settle patent litigation of Daytrana with Noven Pharmaceuticals - 1 views
-
Alex Parker on 24 Mar 14PBR Staff Writer Published 20 March 2014 Ireland-based specialty pharmaceutical firm Actavis has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to its generic version of Daytrana (Methylphenidate Transdermal System). Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.